Antibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10202-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10202-1-AP, RRID:AB_2058661
- Product name
- ARL4C antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated ARL4C antibody (Cat. #10202-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references A multi-dimensional approach to unravel the intricacies of lactylation related signature for prognostic and therapeutic insight in colorectal cancer.
The role of ARL4C in predicting prognosis and immunotherapy drug susceptibility in pan-cancer analysis.
Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions.
CRL5-dependent regulation of the small GTPases ARL4C and ARF6 controls hippocampal morphogenesis.
A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma.
Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer.
ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma.
ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers.
A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.
Huang H, Chen K, Zhu Y, Hu Z, Wang Y, Chen J, Li Y, Li D, Wei P
Journal of translational medicine 2024 Feb 28;22(1):211
Journal of translational medicine 2024 Feb 28;22(1):211
The role of ARL4C in predicting prognosis and immunotherapy drug susceptibility in pan-cancer analysis.
Zhao H, Yang K, Yue Z, Chen Z, Cheng Z, Sun H, Song C
Frontiers in pharmacology 2023;14:1288492
Frontiers in pharmacology 2023;14:1288492
Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
Sheng T, Ho SWT, Ooi WF, Xu C, Xing M, Padmanabhan N, Huang KK, Ma L, Ray M, Guo YA, Sim NL, Anene-Nzelu CG, Chang MM, Razavi-Mohseni M, Beer MA, Foo RSY, Sundar R, Chan YH, Tan ALK, Ong X, Skanderup AJ, White KP, Jha S, Tan P
Genome medicine 2021 Oct 11;13(1):158
Genome medicine 2021 Oct 11;13(1):158
Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions.
Chen X, Zhang Y, Qian W, Han L, Li W, Duan W, Wu Z, Wang Z, Ma Q
iScience 2021 Dec 17;24(12):103400
iScience 2021 Dec 17;24(12):103400
CRL5-dependent regulation of the small GTPases ARL4C and ARF6 controls hippocampal morphogenesis.
Han JS, Hino K, Li W, Reyes RV, Canales CP, Miltner AM, Haddadi Y, Sun J, Chen CY, La Torre A, Simó S
Proceedings of the National Academy of Sciences of the United States of America 2020 Sep 15;117(37):23073-23084
Proceedings of the National Academy of Sciences of the United States of America 2020 Sep 15;117(37):23073-23084
A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma.
Kubota S, Yoshida T, Kageyama S, Isono T, Yuasa T, Yonese J, Kushima R, Kawauchi A, Chano T
World journal of surgical oncology 2020 Oct 22;18(1):270
World journal of surgical oncology 2020 Oct 22;18(1):270
Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer.
Zhang J, Zhang Q, Sun C, Huang Y, Zhang J, Wang Q
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 May;125:110000
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 May;125:110000
ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
Kimura K, Matsumoto S, Harada T, Morii E, Nagatomo I, Shintani Y, Kikuchi A
Cancer science 2020 Mar;111(3):951-961
Cancer science 2020 Mar;111(3):951-961
ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma.
Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, Kageyama S, Kawauchi A, Yonese J, Yuasa T
American journal of cancer research 2019;9(2):415-423
American journal of cancer research 2019;9(2):415-423
ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers.
Wakinoue S, Chano T, Amano T, Isono T, Kimura F, Kushima R, Murakami T
Cancer biomarkers : section A of Disease markers 2019;24(2):223-229
Cancer biomarkers : section A of Disease markers 2019;24(2):223-229
A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.
Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ
Cell 2006 Sep 8;126(5):995-1004
Cell 2006 Sep 8;126(5):995-1004
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ARL4C antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ARL4C. This antibody recognizes human,mouse,rat antigen. The ARL4C antibody has been validated for the following applications: ELISA, IHC analysis.